Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGTNASDAQ:OGINASDAQ:RLAYNASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$7.23-0.1%$5.48$3.72▼$12.61$824.32M1.821.33 million shs4.01 million shsOGIOrganigram Global$1.29-2.3%$1.24$0.85▼$2.08$176.80M1.37658,469 shs673,485 shsRLAYRelay Therapeutics$3.19-5.1%$3.06$1.78▼$10.72$576.05M1.592.09 million shs2.37 million shsVALNValneva$5.66-1.1%$6.39$3.62▼$8.66$486.74M1.8142,658 shs11,596 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-0.14%+2.12%+45.18%+0.98%-14.94%OGIOrganigram Global-2.27%-7.86%-3.73%+16.22%-16.23%RLAYRelay Therapeutics-5.06%-0.93%+11.54%+4.25%-54.62%VALNValneva-1.12%-5.89%-11.97%-21.12%-20.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGTCogent Biosciences1.9352 of 5 stars3.43.00.00.02.00.00.6OGIOrganigram Global1.1227 of 5 stars0.01.00.00.03.20.02.5RLAYRelay Therapeutics2.4837 of 5 stars3.42.00.00.02.12.50.6VALNValneva2.8352 of 5 stars3.55.00.00.03.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.75Moderate Buy$14.57101.54% UpsideOGIOrganigram Global 3.00BuyN/AN/ARLAYRelay Therapeutics 2.83Moderate Buy$17.67453.81% UpsideVALNValneva 3.00Buy$15.50174.05% UpsideCurrent Analyst Ratings BreakdownLatest OGI, COGT, RLAY, and VALN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/29/2025COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $25.005/20/2025COGTCogent BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.005/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.005/7/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.005/7/2025RLAYRelay TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $10.004/17/2025RLAYRelay TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$4.004/15/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/9/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/31/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/24/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $15.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/AOGIOrganigram Global$117.47M1.47N/AN/A$2.07 per share0.62RLAYRelay Therapeutics$10.01M54.64N/AN/A$4.65 per share0.69VALNValneva$183.52M2.62$0.10 per share58.54$2.41 per share2.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$255.86M-$1.84N/AN/AN/AN/A-149.79%-75.61%8/5/2025 (Estimated)OGIOrganigram Global-$33.39M$0.1012.90N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)RLAYRelay Therapeutics-$337.71M-$2.23N/AN/AN/AN/A-44.17%-39.53%8/5/2025 (Estimated)VALNValneva-$13.25M-$1.19N/AN/AN/A-43.08%-43.05%-16.23%8/12/2025 (Estimated)Latest OGI, COGT, RLAY, and VALN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025VALNValneva-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 million5/6/2025Q1 2025COGTCogent Biosciences-$0.56-$0.52+$0.04-$0.52N/AN/A5/5/2025Q1 2025RLAYRelay Therapeutics-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A5.135.13OGIOrganigram GlobalN/A3.421.90RLAYRelay TherapeuticsN/A19.9619.96VALNValneva0.922.702.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/AOGIOrganigram Global34.63%RLAYRelay Therapeutics96.98%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences7.29%OGIOrganigram Global0.09%RLAYRelay Therapeutics4.87%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableOGIOrganigram Global860133.94 million133.82 millionOptionableRLAYRelay Therapeutics330171.45 million163.10 millionOptionableVALNValneva70085.09 million72.41 millionNot OptionableOGI, COGT, RLAY, and VALN HeadlinesRecent News About These CompaniesValneva (NASDAQ:VALN) Shares Gap Down - Should You Sell?June 17, 2025 | marketbeat.comValneva SE (NASDAQ:VALN) Sees Large Drop in Short InterestJune 14, 2025 | marketbeat.comValneva (NASDAQ:VALN) Stock Price Down 4% - Here's What HappenedJune 12, 2025 | marketbeat.comChikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measureJune 10, 2025 | indiaeducationdiary.inUK's MHRA suspends Valneva's chikungunya vaccine for elderlyJune 10, 2025 | reuters.comValneva’s Single-Shot Chikungunya Vaccine Demonstrates Durable Immune Response in ChildrenJune 10, 2025 | pharmexec.comUK restricts use of Valneva chikungunya vaccine for safety reviewJune 10, 2025 | yahoo.comUK's MHRA suspends Valneva's chikungunya vaccine for elderly (June 9)June 10, 2025 | msn.comValneva reports data from Phase II chikungunya vaccine trial in childrenJune 6, 2025 | finance.yahoo.comValneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®June 5, 2025 | globenewswire.comValneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate UpdateJune 4, 2025 | globenewswire.comValneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?June 3, 2025 | marketbeat.comValneva SE (NASDAQ:VALN) Sees Large Decrease in Short InterestJune 2, 2025 | marketbeat.comValneva to Participate at U.S. and European Investor Conferences in JuneMay 26, 2025 | globenewswire.comUS CDC accepts recommendations for chikungunya vaccinesMay 21, 2025 | msn.comLondon man among thousands who've rolled up their sleeves to trial Lyme disease vaccineMay 19, 2025 | cbc.caUS Advises Older Travelers to Avoid Chikungunya VaccineMay 16, 2025 | infectiousdiseaseadvisor.comFDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for SeniorsMay 15, 2025 | pharmexec.comFDA, CDC recommend pause in Valneva chikungunya vaccine for older adultsMay 14, 2025 | cidrap.umn.eduU.S. Advises Older Travelers to Avoid Chikungunya VaccineMay 13, 2025 | usnews.comFDA warns seniors to avoid this vaccine after deadly complicationsMay 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?By Chris Markoch | June 13, 2025View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?Wall Street Sees More Upside for Dell and HPEBy Leo Miller | June 12, 2025View Wall Street Sees More Upside for Dell and HPE3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketBy Chris Markoch | May 22, 2025View 3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketOGI, COGT, RLAY, and VALN Company DescriptionsCogent Biosciences NASDAQ:COGT$7.23 -0.01 (-0.14%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.23 0.00 (0.00%) As of 06/20/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Organigram Global NASDAQ:OGI$1.29 -0.03 (-2.27%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.34 +0.05 (+3.88%) As of 06/20/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Relay Therapeutics NASDAQ:RLAY$3.19 -0.17 (-5.06%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.18 -0.01 (-0.31%) As of 06/20/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Valneva NASDAQ:VALN$5.66 -0.06 (-1.12%) Closing price 06/20/2025 03:58 PM EasternExtended Trading$5.66 0.00 (0.00%) As of 06/20/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
